Advertisement
PCVX vs VIR
Which Stock Would AI Choose? Vaxcyte (PCVX) vs. Vir Biotechnology (VIR) Stock Comparison
Key Takeaways
- Vaxcyte (PCVX) is a clinical-stage vaccine developer whose recent Phase 3 "blue-sky" readout for its VAX-31 pneumococcal vaccine triggered a sharp rally and a multi-billion-dollar market re-rating.
- Vir Biotechnology (VIR) is a smaller-cap biotech pivoting into oncology and hepatitis D, recently swinging to quarterly profitability on collaboration revenue from partners such as Astellas and Gilead.
- The two companies differ sharply in scale, market capitalization, and business focus: PCVX targets a large commercial vaccine market, while VIR leans on earlier-stage pipelines and partnership economics.
- Relative performance has diverged, with PCVX showing strong multi-year momentum and VIR carrying a more volatile, recovery-oriented profile after a long prior decline.
- Both stocks carry binary clinical risk, but PCVX's recent data de-risking and larger analyst conviction contrast with VIR's broader but less-proven catalyst set.
Introduction
Investors evaluating biotechnology often face a choice between a high-momentum, late-stage player and a diversified, earlier-stage developer trading at a lower valuation. This stock comparison of PCVX and VIR frames exactly that trade-off. Both are pre-commercial biotechs, yet their market positioning, catalysts, and recent price behavior could hardly be more different. Growth-oriented traders may find PCVX's clinical momentum compelling, while contrarian and value-oriented investors may weigh VIR's recent financial inflection and partnership-driven pipeline. Understanding the relative performance, risk factors, and sentiment behind each name can help clarify which profile better aligns with a given portfolio objective.
PCVX Overview and Recent Performance
PCVX, or Vaxcyte, is a clinical-stage vaccine company developing conjugate and protein vaccines to prevent bacterial infectious diseases. Its lead candidate, VAX-31, is a 31-strain pneumococcal conjugate vaccine aimed at the adult market dominated by Pfizer's Prevnar 20 and Merck's Capvaxive, with a broader pipeline including VAX-24 and a Group A Streptococcus program.
Recent market activity has centered on a pivotal catalyst: topline results from the OPUS-1 Phase 3 trial, in which VAX-31 met all prespecified primary endpoints and cleared a stricter non-inferiority threshold against both comparator vaccines. Analysts characterized the outcome as near a best-case scenario, with several firms raising price targets substantially. The share price surged in response before giving back some gains after Vaxcyte launched a roughly $1 billion financing combining common stock and convertible notes, a move that briefly pressured shares on dilution concerns. The company remains pre-revenue and cash-burning, with further Phase 3 readouts (OPUS-2 and OPUS-3) expected in the first half of 2027 and a planned regulatory filing in 2028.
VIR Overview and Recent Performance
VIR, or Vir Biotechnology, is a clinical-stage immunology company focused on infectious diseases and oncology. Its pipeline spans a hepatitis D regimen (tobevibart plus elebsiran) in pivotal ECLIPSE trials, plus a family of masked T-cell engagers including VIR-5500 for prostate cancer, VIR-5818 targeting HER2, and VIR-5525 targeting EGFR.
Recent weeks have been shaped by strategic and financial developments rather than a single headline readout. Vir closed collaborations with Astellas and Gilead that delivered substantial upfront cash and equity investments, and its second-quarter 2026 results swung to profitability on collaboration revenue, improving its near-term funding optics. The stock has been more volatile than PCVX, reflecting its smaller market capitalization and a longer-term record marked by a steep multi-year decline followed by a recovery. Analysts maintain a broadly constructive stance, with a consensus "Strong Buy" rating and price targets implying significant upside, but the company's value remains tied to unproven therapies and upcoming trial data across late 2026 and early 2027.
Trending AI Robots
For traders seeking a systematic edge across names like PCVX and VIR, Tickeron's Trending AI Robots page offers a curated view of its AI trading bots. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the best and most suitable for current market conditions earn a place in this curated section — for example, a rotating selection of roughly two dozen top performers chosen from a total pool exceeding 300 bots. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and set of tickers, with reported win rates commonly ranging from roughly 60% to 80% and varying trade durations from intraday to multi-day swings. Exploring the Trending AI Robots section can help you identify the approaches most aligned with today's market environment.
Head-to-Head Comparison
The clearest contrast between these two stocks lies in business model and scale. PCVX is concentrated on a single, high-value franchise — pneumococcal vaccines — where it has already produced late-stage data widely viewed as best-in-class, positioning it against large-cap incumbents in a market estimated in the billions of dollars. VIR, by comparison, runs a diversified portfolio across hepatitis D and multiple oncology assets, which spreads risk but also leaves value dependent on several separate clinical outcomes.
Growth drivers also diverge. PCVX's near-term narrative is anchored by a single de-risking event plus upcoming confirmatory trials, while VIR's drivers include partnership economics, hepatitis D registrational data, and early oncology reads. On risk, PCVX faces dilution and multi-year cash burn, whereas VIR faces lower valuation visibility and historically uneven execution. In terms of market sentiment and relative performance, PCVX has demonstrated stronger and more durable momentum, while VIR offers a lower-priced, higher-beta recovery profile.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst clarity, and relative positioning, Tickeron's AI would likely favor PCVX in the current environment. The stock's recent Phase 3 success, elevated analyst conviction, and clearer path toward a sizable commercial market support a more consistent momentum profile than VIR's. That said, VIR may appeal to AI models emphasizing value and mean-reversion given its lower share price and positive analyst consensus. This assessment reflects probabilistic, data-driven positioning rather than a definitive prediction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCVX is a StrongBuy and VIR is a Hold.
PCVX's Stochastic Oscillator sits in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for PCVX crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +4.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in 225 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for PCVX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 28 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PCVX as a result. In 64 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for PCVX turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 35 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
PCVX moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
PCVX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PCVX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.261) is normal, around the industry mean (3.035). P/E Ratio (-7.920) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
VIR in downward trend: 10-day moving average broke below 50-day moving average on October 22, 2026
The 10-day moving average for VIR crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIR as a result. In 73 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for VIR turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 33 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
VIR moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 59 cases where VIR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
Following a +7.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 202 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 125 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.820) is normal, around the industry mean (3.043). P/E Ratio (-5.972) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PCVX | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 67 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 21 Undervalued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 74 | 100 | |
SMR RATING 1..100 | 96 | 96 | |
PRICE GROWTH RATING 1..100 | 42 | 42 | |
P/E GROWTH RATING 1..100 | 53 | 60 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PCVX's Valuation (21) in the null industry is in the same range as VIR (22). This means that PCVX’s stock grew similarly to VIR’s over the last 12 months.
PCVX's Profit vs Risk Rating (74) in the null industry is in the same range as VIR (100). This means that PCVX’s stock grew similarly to VIR’s over the last 12 months.
PCVX's SMR Rating (96) in the null industry is in the same range as VIR (96). This means that PCVX’s stock grew similarly to VIR’s over the last 12 months.
PCVX's Price Growth Rating (42) in the null industry is in the same range as VIR (42). This means that PCVX’s stock grew similarly to VIR’s over the last 12 months.
PCVX's P/E Growth Rating (53) in the null industry is in the same range as VIR (60). This means that PCVX’s stock grew similarly to VIR’s over the last 12 months.
| PCVX | VIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 74% | N/A |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 68% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 73% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 77% |
| Advances ODDS (%) | 5 days ago 79% | 5 days ago 76% |
| Declines ODDS (%) | 2 days ago 71% | 3 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 73% | 2 days ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PCVX’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- PCVX’s FA Score: 1 green, 4 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PCVX’s TA Score shows that 3 TA indicator(s) are bullish while VIR’s TA Score has 4 bullish TA indicator(s).
- PCVX’s TA Score: 3 bullish, 7 bearish.
- VIR’s TA Score: 4 bullish, 5 bearish.
Price Growth
PCVX (@Biotechnology) experienced а -5.01% price change this week, while VIR (@Biotechnology) price change was +6.12% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
PCVX is expected to report earnings on Nov 03, 2026.
VIR is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NCLO | 25.07 | 0.06 | +0.24% |
| Nuveen AA-BBB CLO ETF | |||
| EFV | 78.84 | -0.22 | -0.28% |
| iShares MSCI EAFE Value ETF (EFV) | |||
| DEMZ | 47.83 | -0.19 | -0.39% |
| Democratic Large Cap Core ETF (DEMZ) | |||
| HAIL | 31.27 | -0.16 | -0.50% |
| State Street SPDR S&P Kensho Smart Mobility ETF (HAIL) | |||
| TAN | 41.07 | -0.28 | -0.68% |
| Invesco Solar ETF (TAN) | |||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | +1.34% | ||
| BEAM - VIR | 55% Loosely correlated | -2.08% | ||
| DNLI - VIR | 53% Loosely correlated | -1.34% | ||
| EDIT - VIR | 52% Loosely correlated | -3.61% | ||
| PRME - VIR | 51% Loosely correlated | -1.61% | ||
| SLDB - VIR | 51% Loosely correlated | -4.36% | ||
More | ||||